Gene expression profiling in familial adenomatous polyposis adenomas and desmoid disease

Hereditary Cancer in Clinical Practice

Volumn 5, Issue 2, 2007, Pages 79-96

  Bowden, Nikola A ^a,b   Croft, Amanda ^a,b   Scott, Rodney J ^a,b,c,d  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^c HAPS Pathology   (Australia)

^d JOHN HUNTER HOSPITAL   (Australia)

Author keywords

Adenomos; Desmoid tumours; FAP; Gene expression profiling

Indexed keywords

ADENOMATOUS POLYP; ADOLESCENT; ADULT; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DESMOID TUMOR; DNA FINGERPRINTING; FAMILIAL DISEASE; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC DIFFERENCE; GENETIC SIMILARITY; HUMAN; HUMAN TISSUE; SCHOOL CHILD;

EID: 34447563849     PISSN: 17312302     EISSN: None     Source Type: Journal    
DOI: 10.1186/1897-4287-5-2-79     Document Type: Article

References (54)

1. Ponz de Leon M, Roncucci L. The cause of colorectal cancer. Dig Liver Dis 2000; 32: 426-439.
2. Sieber OM, Tomlinson IP, Lamlum H. The adenomatous polyposis coli (APC) tumour suppressor - genetics, function and disease. Mol Med Today 2000; 6: 462-469.
3. Giardiello F, Brensinger J, Petersen G. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology 2001; 121: 198-213.
4. Eccles DM, van der Luijt R, Breukel C, Bullman H, Bunyan D, Fisher A, Barber J, du Boulay C, Primrose J, Burn J, Fodde R. Hereditary desmoid disease due to a frameshift mutation at codon 1924 of the APC gene. Am J Hum Genet 1996; 59: 1193-1201.
5. Bonk T, Humeny A, Sutter C, Gebert J, von Knebel Doeberitz M, Becker C-M. Molecular diagnosis of familial adenomatous polyposis (FAP): genotyping of adenomatous polyposis coli (APC) alleles by MALDI-TOF mass spectrometry. Clin Biochem 2002; 35: 87-92.
6. Preston SL, Wong WM, Chan AO, Poulsom R, Jeffery R, Goodlad RA, Mandir N, Elia G, Novelli M, Bodmer WF, Tomlinson IP, Wright NA. Bottom-up histogenesis of colorectal adenomas: origin in the monocryptal adenoma and initial expansion by crypt fission. Cancer Res 2003; 63: 3819-3825.
7. Cruz-Correa M, Giardiello FM. Familial adenomatous polyposis. Gastrointest Endosc 2003; 58: 885-894.
8. Leslie A, Carey FA, Pratt NR, Steele RJ. The colorectal adenoma - carcinoma sequence. Br J Surg 2002; 89: 845-860.
9. Scates D, Clark S, Phillips R, Venitt S. Lack of telomerase in desmoids occurring sporadically and in association with familial adenomatous polyposis. Br J Surg 1998; 85: 965-969.
10. Reitamo J, Scheinin T, Hayry P. The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor. Am J Surg 1986; 151: 230-237.
11. Shields C, Winter D, Kirwan W, Redmond H. Desmoid Tumours. Eur J Surg Oncol 2001; 27: 701-706.
12. Cheon SS, Cheah AY, Turley S, Nadesan P, Poon R, Clevers H, Alman BA. beta-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci U S A 2002; 99: 6973-6978.
13. Brueckl WM, Ballhausen WG, Fortsch T, Gunther K, Fiedler W, Gentner B, Croner R, Boxberger F, Kirchner T, Hahn EG, Hohenberger W, Wein A. Genetic testing for germline mutations of the APC gene in patients with apparently sporadic desmoid tumors but a family history of colorectal carcinoma. Dis Colon Rectum 2005; 48: 1275-1281.
14. Couture J, Mitri A, Lagace R, Smits R, Berk T, Bouchard HL, Fodde R, Alman B, Bapat B. A germline mutation at the extreme 3′ end of the APC gene results in a severe desmoid phenotype and is associated with overexpression of beta-catenin in the desmoid tumor. Clin Genet 2000; 57: 205-212.
15. Alman BA, Li C, Pajerski ME, Diaz-Cano S, Wolfe HJ. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol 1997; 151: 329-334.
16. Cole KA, Krizman DB, Emmert-Buck MR. The genetics of cancer - a 3D model. Nat Genet 1999; 21 (1 Suppl): 38-41.
17. Bucca G, Carruba G, Saetta A, Muti P, Castagnetta L, Smith CP. Gene expression profiling of human cancers. Ann N Y Acad Sci 2004; 1028: 28-37.
18. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531-537.
19. Lin Y-M, Furukawa Y, Tsunoda T, Yue C-T, Yang K-C, Nakamura Y. Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene 2002; 21: 4120-4128.
20. Azumaya M, Kobayashi M, Ajioka Y, Honma T, Suzuki Y, Takeuchi M, Narisawa R, Asakura H. Size-dependent expression of cyclooxygenase-2 in sporadic colorectal polyps relative to adenomas in patients with familial adenomatous polyposis. Pathol Int 2002; 52: 272-276.
21. Brabletz T, Herrmann K, Jung A, Faller G, Kirchner T. Expression of nuclear beta-Catenin and c-myc is correlated with tumor size but not with proliferative activity of colorectal adenomas. Am J Pathol 2000; 156: 865-870.
22. Brosens LA, Iacobuzio-Donahue CA, Keller JJ, Hustinx SR, Carvalho R, Morsink FH, Hylind LM, Offerhaus GJ, Giardiello FM, Goggins M. Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism. Clin Cancer Res 2005; 11: 4090-4096.
23. El-Bahrawy MA, Talbot IC, Poulsom R, Jeffery R, Alison MR. The expression of E-cadherin and catenins in colorectal tumours from familial adenomatous polyposis patients. J Pathol 2002; 198: 69-76.
24. Jungck M, Grunhage F, Spengler U, Dernac A, Mathiak M, Caspari R, Friedl W, Sauerbruch T. E-cadherin expression is homogeneously reduced in adenoma from patients with familial adenomatous polyposis: an immunohistochemical study of E-cadherin, beta-catenin and cyclooxygenase-2 expression. Int J Colorectal Dis 2004; 19: 438-445.
25. Khan KN, Masferrer JL, Woerner BM, Soslow R, Koki AT. Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. Scand J Gastroenterol 2001; 36: 865-869.
26. Dang DT, Bachman KE, Mahatan CS, Dang LH, Giardiello FM, Yang VW. Decreased expression of the gut-enriched Kruppel-like factor gene in intestinal adenomas of multiple intestinal neoplasia mice and in colonic adenomas of familial adenomatous polyposis patients. FEBS Lett 2000; 476: 203-207.
27. Salahshor S, Goncalves J, Chetty R, Gallinger S, Woodgett JR. Differential gene expression profile reveals deregulation of pregnancy specific beta1 glycoprotein 9 early during colorectal carcinogenesis. BMC Cancer 2005; 5: 66.
28. Hlubek F, Pfeiffer S, Budczies J, Spaderna S, Jung A, Kirchner T, Brabletz T. Securin (hPTTG1) expression is regulated by beta-catenin/TCF in human colorectal carcinoma. Br J Cancer 2006; 94: 1672-1677.
29. Pfleghaar K, Heubes S, Cox J, Stemmann O, Speicher MR. Securin is not required for chromosomal stability in human cells. PLoS Biol 2005; 3: e416.
30. Fujii T, Nomoto S, Koshikawa K, Yatabe Y, Teshigawara O, Mori T, Inoue S, Takeda S, Nakao A. Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis. Hepatology 2006; 43: 1267-1275.
31. Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, Melmed S. Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet 2000; 355: 716-719.
32. Cho-Rok J, Yoo J, Jang YJ, Kim S, Chu IS, Yeom YI, Choi JY, Im DS. Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology 2006; 43: 1042-1052.
33. Drivdahl R, Haugk KH, Sprenger CC, Nelson PS, Tennant MK, Plymate SR. Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9. Oncogene 2004; 23: 4584-4593.
34. Blache P, van de Wetering M, Duluc I, Domon C, Berta P, Freund JN, Clevers H, Jay P. SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol 2004; 166: 37-47.
35. Batlle E, Henderson JT, Beghtel H, van den Born MM, Sancho E, Huls G, Meeldijk J, Robertson J, van de Wetering M, Pawson T, Clevers H. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 2002; 111: 251-263.
36. Nakada M, Niska J, Miyamori H, McDonough WS, Wu J, Sato H, Berens ME. The phosphorylation of EphB2 receptor regulates migration and invasion of human glioma cells. Cancer Res 2004; 64: 3179-3185.
37. Wu Q, Suo Z, Risberg B, Karlsson MG, Villman K, Nesland JM. Expression of Ephb2 and Ephb4 in breast carcinoma. Pathol Oncol Res 2004; 10: 26-33.
38. Jager D, Stockert E, Jager E, Gure AO, Scanlan MJ, Knuth A, Old LJ, Chen YT. Serological cloning of a melanocyte rab guanosine 5′-triphosphate- binding protein and a chromosome condensation protein from a melanoma complementary DNA library. Cancer Res 2000; 60: 3584-3591.
39. Li C, Lin M, Liu J. Identification of PRC1 as the p53 target gene uncovers a novel function of p53 in the regulation of cytokinesis. Oncogene 2004; 23: 9336-9347.
40. Sarafan-Vasseur N, Lamy A, Bourguignon J, Le Pessot F, Hieter P, Sesboue R, Bastard C, Frebourg T, Flaman JM. Overexpression of B-type cyclins alters chromosomal segregation. Oncogene 2002; 21: 2051-2057.
41. Skubitz KM, Skubitz AP. Gene expression in aggressive fibromatosis. J Lab Clin Med 2004; 143: 89-98.
42. Denys H, Jadidizadeh A, Amini Nik S, Van Dam K, Aerts S, Alman BA, Cassiman JJ, Tejpar S. Identification of IGFBP-6 as a significantly downregulated gene by beta-catenin in desmoid tumors. Oncogene 2004; 23: 654-664.
43. Katoh Y, Katoh M. Comparative integromics on Ephrin family. Oncol Rep 2006; 15: 1391-1395.
44. Jubb AM, Zhong F, Bheddah S, Grabsch HI, Frantz GD, Mueller W, Kavi V, Quirke P, Polakis P, Koeppen H. EphB2 is a prognostic factor in colorectal cancer. Clin Cancer Res 2005; 11: 5181-5187.
45. Guo DL, Zhang J, Yuen ST, Tsui WY, Chan AS, Ho C, Ji J, Leung SY, Chen X. Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours. Carcinogenesis 2006; 27: 454-464.
46. Lee CH, Bang SH, Lee SK, Song KY, Lee IC. Gene expression profiling reveals sequential changes in gastric tubular adenoma and carcinoma in situ. World J Gastroenterol 2005; 11: 1937-1945.
47. Cox DA. Transforming growth factor-beta 3. Cell Biol Int 1995; 19: 357-371.
48. Riegel AT, Wellstein A. The potential role of the heparin-binding growth factor pleiotrophin in breast cancer. Breast Cancer Res Treat 1994; 31: 309-314.
49. Christman KL, Fang Q, Kim AJ, Sievers RE, Fok HH, Candia AF, Colley KJ, Herradon G, Ezquerra L, Deuel TF, Lee RJ. Pleiotrophin induces formation of functional neovasculature in vivo. Biochem Biophys Res Commun 2005; 332: 1146-1152.
50. DaFonseca CJ, Shu F, Zhang JJ. Identification of two residues in MCM5 critical for the assembly of MCM complexes and Stat1 -mediated transcription activation in response to IFN-gamma. Proc Natl Acad Sci U S A 2001; 98: 3034-3039.
51. O'Kane S, Ferguson MW. Transforming growth factor beta s and wound healing. Int J Biochem Cell Biol 1997; 29: 63-78.
52. Falanga V, Schrayer D, Cha J, Butmarc J, Carson P, Roberts AB, Kim SJ. Full-thickness wounding of the mouse tail as a model for delayed wound healing: accelerated wound closure in Smad3 knock-out mice. Wound Repair Regen 2004; 12: 320-326.
53. Sumiyoshi K, Nakao A, Setoguchi Y, Okumura K, Ogawa H. Exogenous Smad3 accelerates wound healing in a rabbit dermal ulcer model. J Invest Dermatol 2004; 123: 229-236.
54. Yu H, Bock O, Bayat A, Ferguson MW, Mrowietz U. Decreased expression of inhibitory SMAD6 and SMAD7 in keloid scarring. J Plast Reconstr Aesthet Surg 2006; 59: 221-229.